The UK's largest registry of adult twins, or TwinsUK Registry, started in 1992 and encompasses about 12 000 volunteer twins from all over the United Kingdom. More than 70% of the registered twins have filled at least one detailed health questionnaire and about half of them undergone a baseline comprehensive assessment and two follow-up clinical evaluations. The most recent follow-up visit, known as Healthy Ageing Twin Study (HATS), involved 3125 female twins aged 440 years with at least one previous clinical assessment to enable inspection of longitudinal changes in ageing traits and their genetic and environmental components. The study benefits from several state-of-the-art OMICs studies including genome-wide association, next-generation genome and transcriptome sequencing, and epigenetic and metabolomic profiles. This makes our cohort as one of the most deeply phenotyped and genotyped in the world. Several collaborative projects in the field of epidemiology of complex disorders are ongoing in our cohort and interested researchers are encouraged to get in contact for future collaborations.
How did the study come about?
The UK Adult Twin Registry (or TwinsUK Registry) is a cohort of volunteer adult twins from all over the United Kingdom. The Registry was started in 1992 with the primary aim of assessment of heritability of osteoarthritis and osteoporosis in women. The success of early studies led to rapid evolution of the registry and it now incorporates about 12 000 twins, both male and female aged 18-103 years, studied for a whole range of clinical and behavioural traits (Supplementary Appendix A1 available as Supplementary Data at IJE online). The main objective of the original study was to estimate heritabilities for 'common' diseases and traits and to discover associated genes. The details about the aims and design of the original twin registry, facilities and procedures for data collection, clinical and biological assessments, main findings, collaborations and working directions have been published in previous papers 1, 2 and described on the study website (www.twinresearch.ac.uk).
Recently, the view of ageing as an extremely complex multifactorial process involving multiple organs and multiple molecular pathways has replaced the earlier search for a distinct unique cause such as a single gene or the decline of a key body system. 3 Prospective observational twin studies provide an ideal setting for assessment of the genetic and environmental contributions to different ageing mechanisms. Since publication of the last cohort profile in 2006, the aim and focus of our study has been changed to 'healthy ageing'. Age restriction and clinical data collection procedures in the Healthy Ageing Twin Study (HATS; new clinical visit of our cohort) have been modified to measure age-related longitudinal deteriorations in six different organ systems: cardiovascular, muscle, bone, respiration, vision and skin. 'Healthy ageing' is determined by assessment of the over-time changes in quantitative traits (rather than focusing on differences between aged population with/without various disorders) among HATS participants, who are female twins aged 540 years. Alongside detailed clinical measures, the cohort now benefits from several state-of-the-art technologies (the 'OMICs' studies) including data from genomewide association, next-generation genome and transcriptome sequencing, and epigenetic and metabolomic profiles. This paper describes these advances and available opportunities in our cohort.
How is it funded?
Historically, much of the funding for the study has come from the Wellcome Trust project and programme grants and some core funding, with 
What does it cover?
Our study examines the correlation between longitudinal age-related deteriorations in different organ systems, the heritability of biological ageing in different organs, the effects of genetic and environmental factors on biological ageing, and the value of putative biomarkers of ageing. The programme of work to achieve these goals can be summarized in five categories.
(1) Longitudinal data collection: many of the twins in the cohort have at least two clinical visits with biological samples taken (blood, urine and DNA). Several new clinical measures were introduced in the follow-up visits to make HATS into a study of healthy ageing. Who is in the sample, how often have they been followed up and what is attrition like?
The TwinsUK registry is a national twin volunteer population. Twins were recruited through a series of media campaigns asking for volunteers willing to participate in research investigating common diseases. Initially, only middle-aged women were recruited to the registry. 1 From 1995 onwards, men and women 418 years of age were also invited to participate. As a result, 83% of the registry is female. The registry now contains 51% monozygotic (MZ) and 49% dizygotic (DZ) twins aged 18-103 years (Appendix A1 available as Supplementary Data at IJE online).
The flow of the participants through the study is depicted in Figure 1 . Between 1992 and 2004, twins were invited for a comprehensive 'baseline' visit and several project-led studies, which evaluated different aspects of the bone and joint health in middle-aged and older women. Active twins in the registry were contacted in a yearly basis through different postal questionnaires or short follow-up visits. More than 7000 twins responded to annual questionnaires and 5725 of them (out of about 10 000 registered twins) attended a comprehensive visit. About half of them also returned for other visits related to different projects (about 700 twins had four or more visits). Attendants of the comprehensive visit have been compared with a singleton population-based cohort representative of the UK population (Chingford study). 10 Apart from lower weight in MZ twins, all other age-matched characteristics of volunteer twins were found not to differ from singleton women of the same age. Figure 1 ). The study aimed to estimate heritabilities and discover genes for common diseases and complex traits. 2 A sum of 3725 twins attended this visit. Additionally, 1299 twins posted their blood DNA samples (collected via their General Practitioners). The response rate was 55% for the clinical visit and 74% for the DNA sample collection. The age range of participants was 18-82 years (mean 52.5 AE 13 years) and 3299 of the clinic attendants (89%) were female. The data collected in this visit has led to over 80 collaborative and data sharing projects and has contributed to about 170 peer-reviewed publications in the past 3 years (www.twin-research.ac.uk/publications.html).
The second follow-up visit, also known as the HATS visit, started in August 2007 (Figure 1 ). Only women aged 540 years with at least one previous clinical visit were invited (n ¼ 4610) and 3125 women (mean age 59.6 AE 9 years) attended the clinic (response rate ¼ 68%). From 1485 twins who did not attend, 53 were deceased, 646 declined to participate and the remaining 786 could not be contacted. 1498 (48%) of participants were MZ twins as confirmed by genotyping (e.g. GWAS) or 'peas in a pod' questionnaire. 11 Six hundred of the participants in this visit had four or more previous clinical visits. Follow-up time between first and last visits ranged between 6.1 and 17.4 years (mean 11.2 AE 2 years).
General characteristics of the participants in different stages of the study are summarized in Table 1 . Compared with the baseline and first follow-up visits, participants in the HATS visit appeared to have higher socio-economic status, lower self-rated health status and be more health aware given their level of alcohol intake and smoking. Table 2 compares the characteristics of respondents and non-respondents to the HATS invitation based on data from their last clinical visit. These data show that the non-respondents to this visit were generally younger and of lower Table 2 ), suggesting that the participants in this visit could be considered as representative of the original population in the study.
What has been measured?
The structure of the baseline comprehensive and two follow-up visits were quite similar. Twins firstly filled self-completed questionnaires, asking about a range (Table 3) . Twins are all now registered using their National Health Service (NHS) numbers with the Office for National Statistics of England for future follow-up regarding their cancer and mortality status.
Clinical data
As summarized in Table 3 
GWAS
In total, 5710 twins have undergone a genome-wide scan of either 317 000 single nucleotide polymorphism (SNP) markers (Illumina HumanHap300 Bead Chip) or 610 000 SNPs (Illumina HumanHap610 Quad Chip). From these twins, 2840 participated in the first follow-up and 2545 in the second follow-up visits. The data have been fully imputed using IMPUTE version 2 software, 12 quality checked, and used in many international consortia for different phenotypes (Table 4 ). There are several ongoing consortia for meta-analysis of other traits such as lean mass and reproductive health (CHARGE and GEFOS consortia), vitamin D and related traits (SUNLIGHT consortium), molecular phenotypes (MolPAGE consortium), external visible traits (VisiGEN consortium), liver function and other traits (ENGAGE consortium).
Next-generation sequencing
One of the main ongoing collaborations of our department is with the Wellcome Trust Sanger Institute for the UK10K study. Using the state-of-the-art nextgeneration sequencing methods, 13 UK10K aims to find rare genetic variants associated with health and disease. The study involves whole-genome sequencing of 4000 healthy people with well-documented physical characteristics. Two thousands twins from our cohort have been genotyped (6Â depth) in this study. The sequence and clinical data will be publically available soon (www.uk10k.org).
Epigenetics
The EpiTwin study, in collaboration with the Beijing Genomics Institute, is the largest-ever epigenetic project. This study aims to capture the subtle epigenetic signatures that mark the differences between 5000 twins. This will be achieved by Methylated DNA ImmunoPrecipitation (MeDIP) sequencing, examining 'DNA methylation' patterns of 20 million sites across genome of each twin and comparing them with the patterns in the co-twin. Finding the crucial differences between twins will reveal the key genes that are being turned on and off, and so too the causes of diseases. Obesity, diabetes, allergies, heart disease, osteoporosis and longevity are the initial targets of the study (http://www.epitwin.eu).
Gene expression
The MuTHER (Multiple Tissue Human Expression Resource) project is a Wellcome Trust funded study designed to understand the mechanisms involved in common trait susceptibility via gene expression across multiple tissues. The project aims to develop a resource for assessment of the relationships between genome sequence variation, methylation status, mRNA expression and disease phenotypes. 14 Lymphocytes and fat, muscle and skin biopsies have been obtained from 855 twins from the HATS visit. The genome-wide expression profiling of all samples is near complete and GWAS data and DNA methylation data will also be available shortly. Interested researchers can contact us via: muther@kcl.ac.uk.
Specialized tests
Several specialized scans and assays (e.g. spinal Magnetic Resonance Imaging scans and echocardiography) are available in different subsets of twins (Table 3) . Two important ones are 'telomere length' and 'metabolomic' data. In 3256 participants with GWAS data, telomere length has been measured using the Southern blot method on DNA extracted from peripheral leukocytes. These data have contributed to detection of several genes implicated to affect biological age 15, 16 and the collaboration is ongoing. For 1270 twins with GWAS data, fasting serum concentrations of 163 metabolites, covering a biologically relevant panel of amino acids, sugars, acylcarnitines and phospholipids, have been measured using electrospray ionization tandem mass spectrometry (Biocrates AbsoluteIDQ targeted metabolomics technology). Variation in all possible metabolite concentration ratios (163 Â 162 ¼ 26 406 traits), can influence different phenotypes (e.g. osteoarthritis) 17 or be genetically determined. 18 The same sample has also been assayed for non-targeted metabolomics using ultrahigh performance liquid-phase chromatography and gas chromatography separation coupled with tandem mass spectrometry. Quality of life (SF-
Lung function tests 3 3 3
Hip and spine DXA 3 3 3
Whole-body DXA (fat and lean mass) Visual acuity and refractive errors 3 3 3
Intraocular pressure and optic disc photo --3
Cataract (lens opacity) 3 -3
Macular degeneration and fundus photo 3 -3
Facial features (2-and 3-dimensional images) 3 3 3
Pain perception tests -3 3
Distorted tune test -3 3
Hearing loss and audiometry --3
Naevi counts -3 3
Genetic assessments
Whole-genome next-generation sequencing -3 3
Epigenetic analysis (MeDIP sequencing) -3 3
Gene expression (RNA sequencing) --3
Specialized tests (not performed on all participants)
TWINSUK AND HEALTHY AGEING TWIN STUDY
What has it found?
TwinsUK contributions to science have evolved with the advances, in both methodology and technology, over the past two decades. In the early stages, linkage studies in twins found several replicated loci for different ageing traits such as bone mineral density 19 and telomere shortening. 20 Heritability of many complex traits, from obvious clinical endpoints (e.g. blood pressure 21 and cataract) 22 to non-clinical personalityrelated traits (e.g. sexual functioning 23 or entrepreneurship), 24 have been estimated in this cohort. Nearly all traits measured to date show a heritable component. Interestingly, many diseases previously believed to be dull 'wear and tear' diseases (such as degenerative disc disease or osteoarthritis) have a major genetic component. TwinsUK has particularly contributed to the clinical and genetic epidemiology of osteoporosis and osteoarthritis. We have collaborated with several GWAS consortia that have found polymorphisms associated with several important clinical conditions (Table 4) . Recently, we showed that $50-60% of biological variations in metabolite concentrations in plasma and urine are related to familial and environmental factors. 25 GWAS of approximately 37 000 metabolomic traits also identified several genes involved in metabolic individuality in humans. 26 Unusually high effect sizes for some of these traits promise significant advances in future functional studies. Work on several projects like UK10K, EpiTwin, MuTHER and EuroBATS is ongoing by several groups in our department. For a comprehensive list of publications, interested researchers can refer to http://www. twin-research.ac.uk/publications.html.
What are the main strengths?
The twin-based nature of this cohort, frequent data collection and detailed characterization of participants enables researchers to dissect the contribution of genetic and environmental risk factors for complex diseases and domains of healthy ageing. All measurements have been made by a trained research team working with strict study protocols for about two decades. Blood, urine and DNA samples from all visits are stored for future measurements. Follow-up for cause-specific mortality and cancer is ongoing for all participants. We are moving towards new methods of active engagement with twins (e.g. email lists and social networking websites). The current plan is to What are the main weaknesses?
The UK Adult Twin Registry is based on volunteer subjects, which might be considered as nonrepresentative of the total population. Twins may also differ from singleton populations in several in utero or early-life exposures and this is a potential limitation of all twin studies. We have compared our twins with a population-based study sample and found no important clinical differences. 10 The status of participants in the last clinical visit (Table 2 ) also shows no sign of attrition bias. Given the variable structure of the baseline visits (before 2004), and the fact that TwinsUK study was not founded as a usual longitudinal cohort, there are missing values for some of the study measures for different sub-samples. Currently, a specialized group inside our department is working on cleaning and harmonizing data. At this time, our study population might be considered somewhat young for an ageing study with mean age of 61 years and only $10% aged 475 years. We prefer to describe this as an 'early ageing' cohort. Hence, most of our health outcomes are quantitative traits rather than discrete endpoints (such as end-stage diseases). The advantage is, however, that we can study them prospectively and useful data will continue to emerge from future evaluations.
Can I get hold of the data? Where can I find out more?
Invaluable data have been gathered within the TwinsUK and HATS study that may provide answers to hundreds of research questions about the healthy ageing process. These cannot all be analysed by our research group alone and we believe this is the best time for new collaborators to join our study. One of our missions is to collaborate with other groups and promote the wide use of our data. There is an embedded search engine in our website (www .twin-research.ac.uk/phenotypes.html) that researchers can enter their phenotype of interest and find the relevant assessments performed in different stages of our study. We invite colleagues to find out if TwinsUK data can help them answer their research questions. Contact information can be found at the study website: www.twin-research.ac.uk.
Supplementary Data
Supplementary Data are available at IJE online.
